Evaluating tacrolimus pharmacokinetic models in adult renal transplant recipients with different CYP3A5 genotypes
- 281 Downloads
Numerous studies have been conducted on the population pharmacokinetics of tacrolimus in adult renal transplant recipients. It has been reported that the cytochrome P450 (CYP) 3A5 genotype is an important cause of variability in tacrolimus pharmacokinetics. However, the predictive performance of population pharmacokinetic (PK) models of tacrolimus should be evaluated prior to their implementation in clinical practice. The aim of the study reported here was to test the predictive performance of these published PK models of tacrolimus.
A literature search of the PubMed and Web of Science databases ultimately led to the inclusion of eight one-compartment models in our analysis. We collected a total of 1715 trough concentrations from 174 patients. Predictive performance was assessed based on visual and numerical comparison bias and imprecision and by the use of simulation-based diagnostics and Bayesian forecasting.
Of the eight one-compartment models assessed, seven showed better predictive performance in CYP3A5 extensive metabolizers in terms of bias and imprecision. Results of the simulation-based diagnostics also supported the findings. The model based on a Chinese population in 2013 (model 3) showed the best and most stable predictive performance in all the tests and was more informative in CYP3A5 extensive metabolizers. As expected, Bayesian forecasting improved model predictability. Diversity among models and between different CYP3A5 genotypes of the same model was also narrowed by Bayesian forecasting.
Based on our results, we recommend using model 3 in CYP3A5 extensive metabolizers in clinical practice. All models had a poor predictive performance in CYP3A5 poor metabolizers, and they should be used with caution in this patient population. However, Bayesian forecasting improved the predictability and reduced differences, and thus the models could be applied in this latter patient population for the design of maintenance dose.
KeywordsPopulation pharmacokinetics Tacrolimus Evaluation Renal transplant
CH, LYZ, JLW, JJD and XCZ participated in study design. CH, RRM and XCZ performed the research. CH, KL and GZ collected and analysed data. HC, WJY, DYL, and XCZ wrote the paper.
This study was funded by the National Natural Science Foundation of China (81773822) and the New Xiangya Talent Project of the Third Xiangya Hospital of Central South University (No.20150218).
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
Ethical and regulatory approval was approved by the Ethical Committee of the Third Xiangya Hospital of Central South University (No. 2018-S225). All procedures in this study were carried out according to the 1964 Helsinki Declaration and its later amendments.
- 3.Webster A, Woodroffe RC, Taylor RS, Chapman JR, Craig JC (2005) Tacrolimus versus cyclosporin as primary immunosuppression for kidney transplant recipients. Cochrane Database Syst Rev (4):D3961. https://doi.org/10.1002/14651858.CD003961.pub2
- 4.Anglicheau D, Verstuyft C, Laurent-Puig P, Becquemont L, Schlageter MH, Cassinat B, Beaune P, Legendre C, Thervet E (2003) Association of the multidrug resistance-1 gene single-nucleotide polymorphisms with the tacrolimus dose requirements in renal transplant recipients. J Am Soc Nephrol 14(7):1889–1896CrossRefPubMedGoogle Scholar
- 8.Benkali K, Premaud A, Picard N, Rerolle JP, Toupance O, Hoizey G, Turcant A, Villemain F, Le Meur Y, Marquet P, Rousseau A (2009) Tacrolimus population pharmacokinetic-pharmacogenetic analysis and Bayesian estimation in renal transplant recipients. Clin Pharmacokinet 48(12):805–816. https://doi.org/10.2165/11318080-000000000-00000 CrossRefPubMedGoogle Scholar
- 9.Press RR, Ploeger BA, den Hartigh J, van der Straaten T, van Pelt J, Danhof M, de Fijter JW, Guchelaar HJ (2009) Explaining variability in tacrolimus pharmacokinetics to optimize early exposure in adult kidney transplant recipients. Ther Drug Monit 31(2):187–197. https://doi.org/10.1097/FTD.0b013e31819c3d6d CrossRefPubMedGoogle Scholar
- 11.Benkali K, Rostaing L, Premaud A, Woillard JB, Saint-Marcoux F, Urien S, Kamar N, Marquet P, Rousseau A (2010) Population pharmacokinetics and Bayesian estimation of tacrolimus exposure in renal transplant recipients on a new once-daily formulation. Clin Pharmacokinet 49(10):683–692. https://doi.org/10.2165/11535950-000000000-00000 CrossRefPubMedGoogle Scholar
- 12.Woillard J, de Winter BCM, Kamar N, Marquet P, Rostaing L, Rousseau A (2011) Population pharmacokinetic model and Bayesian estimator for two tacrolimus formulations—twice daily Prograf® and once daily Advagraf®. Brit J Clin Pharmacol 71(3):391–402. https://doi.org/10.1111/j.1365-2125.2010.03837.x CrossRefGoogle Scholar
- 15.Musuamba FT, Mourad M, Haufroid V, Demeyer M, Capron A, Delattre IK, Delaruelle F, Wallemacq P, Verbeeck RK (2012) A simultaneous D-optimal designed study for population pharmacokinetic analyses of mycophenolic acid and tacrolimus early after renal transplantation. J Clin Pharmacol 52(12):1833–1843. https://doi.org/10.1177/0091270011423661 CrossRefPubMedGoogle Scholar
- 16.Gaïes E, Mongi Bacha M (2013) Tacrolimus population pharmacokinetics and bayesian estimation in Tunisian renal transplant recipients. Int J Pharm Pharm Sci 5(3):108–115Google Scholar
- 17.Han N, Yun H, Hong J, Kim I, Ji E, Hong SH, Kim YS, Ha J, Shin WG, Oh JM (2013) Prediction of the tacrolimus population pharmacokinetic parameters according to CYP3A5 genotype and clinical factors using NONMEM in adult kidney transplant recipients. Eur J Clin Pharmacol 69(1):53–63. https://doi.org/10.1007/s00228-012-1296-4 CrossRefPubMedGoogle Scholar
- 18.Ogasawara K, Chitnis SD, Gohh RY, Christians U, Akhlaghi F (2013) Multidrug resistance-associated protein 2 (MRP2/ABCC2) haplotypes significantly affect the pharmacokinetics of tacrolimus in kidney transplant recipients. Clin Pharmacokinet 52(9):751–762. https://doi.org/10.1007/s40262-013-0069-2 CrossRefPubMedCentralPubMedGoogle Scholar
- 19.Sberg A, Midtvedt K, van Guilder M, St Rset E, Bremer S, Bergan S, Jelliffe R, Hartmann A, Neely MN (2013) Inclusion of CYP3A5 genotyping in a nonparametric population model improves dosing of tacrolimus early after transplantation. 26(12):1198–1207. https://doi.org/10.1111/tri.12194 CrossRefPubMedGoogle Scholar
- 20.Zuo X, Ng CM, Barrett JS, Luo A, Zhang B, Deng C, Xi L, Cheng K, Ming Y, Yang G, Pei Q, Zhu L, Yuan H, Liao H, Ding J, Wu D, Zhou Y, Jing N, Huang Z (2013) Effects of CYP3A4 and CYP3A5 polymorphisms on tacrolimus pharmacokinetics in Chinese adult renal transplant recipients. Pharmacogenet Genomics 23(5):251–261. https://doi.org/10.1097/FPC.0b013e32835fcbb6 CrossRefPubMedGoogle Scholar
- 21.Golubović B, Vučićević K, Radivojević D, Kovačević SV, Prostran M, Miljković B (2014) Total plasma protein effect on tacrolimus elimination in kidney transplant patients—population pharmacokinetic approach. Eur J Pharm Sci 5234–5240. doi: https://doi.org/10.1016/j.ejps.2013.10.008 CrossRefPubMedGoogle Scholar
- 24.Størset E, Holford N, Hennig S, Bergmann TK, Bergan S, Bremer S, Åsberg A, Midtvedt K, Staatz CE (2014) Improved prediction of tacrolimus concentrations early after kidney transplantation using theory-based pharmacokinetic modelling. Brit J Clin Pharmacol 78(3):509–523. https://doi.org/10.1111/bcp.12361 CrossRefGoogle Scholar
- 26.Zhang J, Liu S, Xue L, Ding X, Zhang H, Miao L (2015) The genetic polymorphisms of POR*28 and CYP3A5*3 significantly influence the pharmacokinetics of tacrolimus in Chinese renal transplant recipients. Int J Clin Pharmacol Ther 53(09):728–736. https://doi.org/10.5414/CP202152 CrossRefPubMedGoogle Scholar
- 28.Vadcharavivad S, Praisuwan S, Techawathanawanna N, Treyaprasert W, Avihingsanon Y (2016) Population pharmacokinetics of tacrolimus in Thai kidney transplant patients: comparison with similar data from other populations. J Clin Pharm Ther 41(3):310–328. https://doi.org/10.1111/jcpt.12396 CrossRefPubMedGoogle Scholar
- 30.Andreu F, Colom H, Elens L, van Gelder T, van Schaik RHN, Hesselink DA, Bestard O, Torras J, Cruzado JM, Grinyó JM, Lloberas N (2017) A new CYP3A5*3 and CYP3A4*22 cluster influencing tacrolimus target concentrations: a population approach. Clin Pharmacokinet 56(8):963–975. https://doi.org/10.1007/s40262-016-0491-3 CrossRefPubMedGoogle Scholar
- 31.Parente L (2017) Deflazacort: therapeutic index, relative potency and equivalent doses versus other corticosteroids. BMC Pharmacol Toxicol 18:1. https://doi.org/10.1186/s40360-016-0111-8
- 33.Bloomfield C, Staatz CE, Unwin S, Hennig S (2016) Assessing predictive performance of published population pharmacokinetic models of intravenous tobramycin in pediatric patients. Antimicrob Agents Chemother 60(6):3407–3414. https://doi.org/10.1128/AAC.02654-15 CrossRefPubMedCentralPubMedGoogle Scholar
- 34.Barraclough KA, Isbel NM, Kirkpatrick CM, Lee KJ, Taylor PJ, Johnson DW, Campbell SB, Leary DR, Staatz CE (2011) Evaluation of limited sampling methods for estimation of tacrolimus exposure in adult kidney transplant recipients. Brit J Clin Pharmacol 71(2):207–223. https://doi.org/10.1111/j.1365-2125.2010.03815.x CrossRefGoogle Scholar
- 37.Watanabe M, Fukuoka N, Takeuchi T, Yamaguchi K, Motoki T, Tanaka H, Kosaka S, Houchi H (2014) Developing population pharmacokinetic parameters for high-dose methotrexate therapy: implication of correlations among developed parameters for individual parameter estimation using the Bayesian least-squares method. Biol Pharm Bull 37(6):916–921CrossRefPubMedGoogle Scholar
- 40.Li JL, Wang XD, Chen SY, Liu LS, Fu Q, Chen X, Teng LC, Wang CX, Huang M (2011) Effects of diltiazem on pharmacokinetics of tacrolimus in relation to CYP3A5 genotype status in renal recipients: from retrospective to prospective. Pharmacogenomics J 11(4):300–306. https://doi.org/10.1038/tpj.2010.42 CrossRefPubMedGoogle Scholar
- 46.Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, Watkins PB, Daly A, Wrighton SA, Hall SD, Maurel P, Relling M, Brimer C, Yasuda K, Venkataramanan R, Strom S, Thummel K, Boguski MS, Schuetz E (2001) Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 27(4):383–391. https://doi.org/10.1038/86882 CrossRefPubMedGoogle Scholar
- 50.de Jonge H, Vanhove T, de Loor H, Verbeke K, Kuypers DR (2015) Progressive decline in tacrolimus clearance after renal transplantation is partially explained by decreasing CYP3A4 activity and increasing haematocrit. Br J Clin Pharmacol 80(3):548–559. https://doi.org/10.1111/bcp.12703 CrossRefPubMedCentralPubMedGoogle Scholar